上海捷世凯生物科技有限公司欢迎您!
销售主管 朱如燕 13795461237
阿巴瑞克
Abarelix
T10217L-50mg
183552-38-7
TargetMol
1416.06
C72H95ClN14O14
¥2970.00
100.00%
50mg
无质量问题不做退换货处理,下单前请仔细确认,感谢配合!

商品介绍

Product Introduction

Bioactivity

名称Abarelix
描述Abarelix (PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, which is used for prostate cancer treatment.
体外活性Abarelix(30及300µg/mL)显著增加组胺释放[1]。Abarelix是首个开发出的促性腺激素释放激素(GnRH)拮抗剂,它能够在不需要联合抗雄激素治疗的情况下,迅速且持续地将睾酮降至阉割水平,并且在短期内并发症率低[2]。Abarelix 不会导致血清睾酮水平激增从而引起病情突发或恶化,它能更快地实现医学阉割[3]。
存储条件keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
溶解度DMSO : 14.2 mg/mL (10.03 mM), Sonication is recommended.
关键字R-3827 | R 3827 | PPI-149 | PPI149 | Inhibitor | inhibit | Gonadotropin releasing hormone receptor | GNRHReceptor | GnRHR | GNRHR | GNRH Receptor | GnRH Receptor | Abarelix
相关产品Danazol | Cetrorelix diacetate | Opigolix | Goserelin acetate | AG 045572 | Relugolix | Cetrorelix Acetate | Linzagolix choline | LGnRH-III, lamprey acetate(147859-97-0 free base) | Lecirelin acetate(61012-19-9 free base) | Ganirelix Acetate | Alarelin Acetate
相关库Inhibitor Library | Bioactive Compound Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | Bioactive Compounds Library Max | Peptide Compound Library | FDA-Approved Drug Library | GPCR Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Drug Library

质检报告

文件下载